New combo therapy tested to shrink aggressive breast tumors before surgery
NCT ID NCT07283692
Summary
This study is testing whether adding an immunotherapy drug called SERplulimab to standard chemotherapy helps shrink tumors more effectively before surgery in people with triple-negative breast cancer. It will involve about 46 women with early-stage disease to see if this combination leads to no detectable cancer in the surgically removed tissue and to monitor side effects. The goal is to improve outcomes by reducing cancer burden before an operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, 200127, China
Conditions
Explore the condition pages connected to this study.